Overview

A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Cancer

Status:
NOT_YET_RECRUITING
Trial end date:
2028-06-19
Target enrollment:
Participant gender:
Summary
The study is to explore the the reasonable dosage and to evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in combination with Serplulimab (anti-PD-1 humanized monoclonal antibody injection) in patients with advanced lung cancer.
Phase:
PHASE2
Details
Lead Sponsor:
Shanghai Henlius Biotech